Abstract:Anaplastic lymphoma kinase (ALK) rearrangement occurs in approximately 5% of NSCLCs and confers sensitivity to ALK tyrosine kinase inhibitors (TKIs).1Rodig S.J. Shapiro G.I. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.Curr Opin Investig Drugs. 2010; 11: 1477-1490PubMed Google Scholar The major acquired resistance mechanisms to ALK TKIs are secondary ALK mutations and coexistence of somatic mutations; the other resistance mechanisms are yet to be revealed.2Yu Y. Ou Q. Wu X. et al.Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.Lung Cancer. 2019; 127: 19-24Abstract Full Text Full Text PDF PubMed Scopus (13) Google Scholar Here, we describe the sustained response to second-line crizotinib in two patients with echinoderm microtubule-associated protein-like 4 (EML4)-ALK-rearranged advanced NSCLC after failure of the first-line alectinib therapy with no secondary ALK mutations. The first patient was a 47-year-old man who was diagnosed with an ALK-positive lung adenocarcinoma, cT4N3M1c (Fig. 1A). Next-generation sequencing (NGS) analysis of pretreatment plasma revealed EML4-ALK fusion (E6:A20) (3.12%) and TP53 R273C mutation. From August 19, 2016, the patient received alectinib treatment and achieved a partial response (PR) after 8 weeks (Fig. 1B). After 32 weeks, the plasma NGS revealed a decreased allelic fraction of the EML4-ALK fusion (0.14%) and the computed tomography scan still showed a PR (Fig. 1C). After 40 weeks, contrast computed tomography scan indicated progressive disease (PD) (Fig. 1D) with an increased allelic fraction of the EML4-ALK fusion (1.26%). The patient was switched to crizotinib because no targetable mutations or other secondary ALK mutations were detected, and he achieved a PR (Fig. 1E) after 4 weeks. He has been on crizotinib therapy for about 31 months and continues to respond to crizotinib until the time of this manuscript preparation (Fig. 1F). Interestingly, the plasma NGS performed on December 2019 revealed the disappearance of the EML4-ALK fusion (Table 1).Table 1Plasma NGS of Patient 1 During the TreatmentDateTumor ResponseVariation Detected by NGSAbundance (Allelic Fraction)2016/08/17BaselineEML4-ALK (E6:A20)3.12%2017/03/31PR after 32 weeks of alectinibEML4-ALK (E6:A20)0.14%2017/05/22PD after 40 weeks of alectinibEML4-ALK (E6:A20)1.26%2019/12/11Sustained PR after 30 months of crizotinibNone0NGS, next-generation sequencing; PR, partial response; PD, progressive disease. Open table in a new tab NGS, next-generation sequencing; PR, partial response; PD, progressive disease. Another 55-year-old man was diagnosed with an ALK-positive cT4N3M1a lung adenocarcinoma (Fig. 2A). NGS analysis of both plasma and tumor tissue revealed EML4-ALK fusion (E13:A20), with CCND1 missense mutation detected only from the tumor tissue. The patient received first-line alectinib therapy since April 28, 2017, with a PR (Fig. 2B) until 40 weeks of alectinib therapy. The plasma NGS revealed that the EML4-ALK fusion disappeared after 16 weeks and 24 weeks but reappeared after 40 weeks of alectinib therapy (Table 2). On March 28, 2018, computed tomography scan revealed aggravation of the carcinomatous lymphangitis and increased pleural effusion (Fig. 2C). Then, the patient’s treatment was switched to crizotinib for the same reason as the first patient. The second-line crizotinib treatment led to a marked regression of the carcinomatous lymphangitis (Fig. 2D), and this effect lasted for 10 months.Table 2Plasma NGS of Patient 2 During the TreatmentDateTumor ResponseVariation Detected by NGSAbundance (Allelic Fraction)2017/04/28BaselineEML4-ALK (E13:A20)0.36%2017/08/18PR after 16 weeks of alectinibnone02017/10/13PR after 24 weeks of alectinibnone02018/02/02PD after 40 weeks of alectinibEML4-ALK (E13:A20)1.21%2018/03/22PD after 48 weeks of alectinibEML4-ALK (E13:A20)1.15%2018/06/03PR after 2 months of crizotinibnone0NGS, next-generation sequencing; PR, partial response; PD, progressive disease. Open table in a new tab NGS, next-generation sequencing; PR, partial response; PD, progressive disease. Two previous reports have already established the efficacy of crizotinib after failure of alectinib; however, the findings from our cases are still noteworthy.3Gouji T. Takashi S. Mitsuhiro T. Yukito I. Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor?.J Thorac Oncol. 2014; 9: e27-e28Abstract Full Text Full Text PDF PubMed Scopus (64) Google Scholar,4Kashima J. Okuma Y. Hishima T. A patient previously treated with ALK inhibitors for central nervous system lesions from ALK rearranged lung cancer: a case report.OncoTargets Ther. 2016; 9: 6059-6063Crossref PubMed Scopus (3) Google Scholar First, our cases revealed that dynamic treatment monitoring using plasma NGS can allow assessment of treatment efficacy and guide treatment options after developing resistance. Second, the underlying mechanisms are different from both those previous reports; neither alternative cell proliferation pathways nor history of chemotherapy or radiotherapy were observed in our patients. Moreover, their median progression-free survival was comparable or even longer than the median progression-free survival of naive patients with ALK rearrangement.5Noonan S.A. Camidge D.R. PROFILE 1014: lessons for the new era of lung cancer clinical research.Transl Lung Cancer Res. 2015; 4: 642-648PubMed Google Scholar We speculate that the sustained response to crizotinib in our cases was primarily owing to the absence of ALK resistance mutations. However, we cannot completely rule out the activation of other alternative pathways, as tumor rebiopsies were not performed after developing resistance to alectinib. Dr. Zheng received the grant from Zhejiang Provincial Natural Science Foundation (grant number: LGF19H160031 to Jing Zheng).

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials

Efficacy of Brigatinib in Patients with Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of Brigatinib-2 (ALTA-2)

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

Brigatinib Versus Alectinib in ALK-Positive NSCLC after Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial

Brigatinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer: Final results of the phase 2 J‐ALTA trial

Brigatinib: Novel ALK Inhibitor for Non–Small-Cell Lung Cancer

Brigatinib vs Alectinib in Crizotinib-Resistant Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer (ALTA-3)

Phase III ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)−positive non–small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ)

Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study

Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer

Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib Versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer

Sustained Response to Crizotinib after Resistance to First-Line Alectinib Treatment in Two Patients with ALK-Rearranged NSCLC.

Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer

Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison

Brigatinib: A Review in ALK-Inhibitor Naïve Advanced ALK-Positive NSCLC

Long ‐ Term Effects of Crizotinib in ALK ‐ Positive Tumors ( Excluding NSCLC ) : A Phase 1 B Open ‐ Label Study

Brigatinib as a treatment of ALK-positive non-small cell lung cancer

Final Overall Survival, Safety, and Quality of Life Results from a Phase 2 Study of Crizotinib in East Asian Patients with ROS1-Positive Advanced NSCLC

Phase 3 Study of First-Line Crizotinib Vs Pemetrexed−cisplatin/carboplatin (PCC) in East Asian Patients (pts) with ALK+ Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC).

Results of a global phase II study with crizotinib in advanced ALK-positive non-small-cell lung cancer (NSCLC)

Q-TWiST analysis of survival benefits with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer based on results of the ALTA-1L trial